Johnson & Johnson Tops Q4 EPS Forecasts

Pharmaceuticals and medical devices manufacturer Johnson & Johnson (NYSE:JNJ) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 billion came in just ahead of forecasts for $22.4 billion while adjusted earnings per share (EPS) of $2.04 also surpassed the $1.99 estimate. Although sales surged in the Innovative Medicine and MedTech segments, patent expirations and regulatory challenges remain concerns. Overall, Johnson & Johnson had a strong quarter, continuing to expand its product pipeline and positioning itself well amid market fluctuations.Source: Johnson & Johnson. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool